tional and bilateral initiatives, including WHO's '3 by 5' target (3 million patients treated by 2005), the Global Fund to fight AIDS, Tuberculosis and Malaria, and the United States President's Emergency Plan for AIDS Relief (PEPFAR), aim to substantially increase access to antiretroviral treatment in these settings during the next few months.
Clinical and epidemiological research has been conducted at the level of selected centres regarding treatment response, [5] [6] [7] [8] programme management, 9 ,10 the use of generic medications, 11, 12 occurrence of side effects, 13 and adherence to treatment. 14, 15 However, data are still limited and the World Health Organization (WHO) and others have called for a focused operational research agenda, which will produce data on 'what works, what does not work, and why'. 16 As the 'scaling-up' of antiretroviral treatment proceeds rapidly, it is imperative that this research be timely and rooted in routine clinical management. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, a network of HIV/AIDS treatment programmes and cohorts in Africa, South America, and Asia was set up in 2003 to address these questions.
Who set ART-LINC up and how is it funded?
The coordinating team (see Appendix) identified potential clinical sites and cohorts treating HIV-infected patients with HAART in resource-limited settings by screening abstracts of international conferences, performing MEDLINE searches, and through personal contacts. The ART-LINC Collaboration is funded by the National Institutes of Health (Office of AIDS Research) in the United States, and the Agence Nationale de Recherches sur le Sida (ANRS) in France. Centres have recruited their cohorts and organized follow-up of patients locally. Funding to ART-LINC is devoted to coordination, training, and support in standardizing and harmonizing data collection, quality assessment and control, and data management and statistical analysis of pooled data.
What does ART-LINC cover and who is included in the sample?
The three primary objectives of ART-LINC are (i) to define the prognosis of HIV-1 infected patients treated with HAART in resource-limited settings; (ii) to compare the experience between different settings, delivery modes and types of monitoring; and (iii) to compare prognosis in resource-limited settings with that observed in industrialized nations. (Figure 1 ). At all sites local ethics committees or institutional review boards had approved the collection of data. Table 1 . Nine centres (39%) were public, generally funded through the Ministries of Health. The remaining were either private for-profit (n 5 4), or private not-for-profit programmes run by non-governmental organizations (NGOs) (n 5 10). At the end of 2003 the median number of HIV-infected patients registered was 1800 per programme (range: 79-7000) and the median number of HAART-treated patients was 542 (range: 70-3000) ( Table 1) . Six programmes had multiple treatment sites and 15 treated children as well as adults. Levels of staffing of HIV/AIDS care programmes varied, with a median number of nine medical doctors, medical assistants or nurses per centre (range: 3-42), or a median ratio of 160 HIV-infected patients per staff member (range: 26-1167). In nine centres antiretroviral drugs were primarily supplied by government and 16 centres reported having access to generic drugs. Costs to patients varied: 12 programmes charged for drugs (median: 31 US dollars; range: 8-198 US dollars per month), 14 for CD4 1 Tlymphocyte counts (CD4 counts; median: 23.5 US dollars; range: 10-33.5 US dollars per measurement) and 10 charged consultation fees (median: 6 US dollars; range: 1-44.4 US dollars per consultation). HIV-1 plasma viral load determinations were available in 17 centres but cost was high (50-100 US dollars) and testing was infrequent. Eleven centres provided free care (free drugs and no consultation fee, or a minimal one according to local standards).
Characteristics of treatment programmes
The centres' eligibility criteria for initiating HAART were advanced immunodeficiency (CD4 cell count ,200 cells/ml or ,350 cells/ml) or advanced clinical disease according to WHO or CDC stages. Pre-treatment counselling or psycho-social preparation were part of the protocol in 18 centres. Most programmes were associated with or provided other services, including voluntary counselling and testing (18 centres), prevention of mother to child transmission (15 centres), and specialized tuberculosis clinics (13 centres). Eighteen centres had systems in place for tracing patients lost to follow-up, using telephones or home visits.
Patient characteristics
The current dataset from the ART-LINC collaboration includes a total of 8734 patients. Table 2 shows the characteristics at the start of HAART of the 7075 individuals with complete sociodemographic data, known date of starting HAART, and at least one follow-up visit, separately for treatment-naïve and treatment-experienced patients, and patients with and without baseline CD4 cell measurements. The majority of patients (n 5 6498, 92%) were treatment-naïve and 73% (n 5 5193) had a CD4 count at baseline. Compared with treatment-naïve patients, treatment-experienced patients were more likely to be men (65% vs 54%; P , 0.001), to have started HAART before 2002 (49% vs 25%; P , 0.001), and less likely to be treated in a public clinic (42% vs 67%; P , 0.001). Treatment-experienced patients had higher baseline CD4 counts at the time of HAART initiation, although both in treatment-experienced and treatment-naïve patients median baseline CD4 counts were ,200 cells/mm 3 . Compared with patients starting HAART without an immunological assessment, those with a documented baseline CD4 count were less likely to be male (49% vs 69%; P , 0.001) and more likely to be treated in publicly funded centres (75% vs 42%; P , 0.001) or programmes offering free care (49% vs 19%; P , 0.001). The proportion of patients starting HAART with a documented baseline CD4 count was lower in the most recent calendar period (2002) (2003) compared with the earlier periods (71% vs 86%; P , 0.001). Table 3 summarizes the antiretroviral combinations most commonly prescribed. Overall, the most prescribed combination was stavudine (d4T), lamivudine (3TC), and nevirapine (NVP) (41%). These three drugs were given separately in 22% of all prescriptions, but clinics in the Southern Africa region mainly used the generic fixed-dose combination TriomuneÔ. Zidovudine (ZDV), 3TC, and efavirenz (EFZ) (11%), ZDV, 3TC, and NVP (9%) and d4T, 3TC, and EFZ (6%) were also commonly used drug combinations. Altogether, the four WHO recommended first-line HAART regimens 16 Figure 2 ).
Treatment regimens

How often are participants followed-up and what is measured?
The frequency of follow-up visits varies by cohort and by patient, depending on the clinical status of the patient, time since initiation of treatment (i.e. follow-up visits are recommended to be more frequent in the first weeks and months), and the presence of co-morbidities and adverse effects. Measurements of CD4 counts are planned every 4-6 months. Using a standardized, field-tested site assessment tool, the characteristics of treatment programmes were recorded in late 
What is attrition like?
At present attrition is difficult to estimate because the duration of follow-up is limited. We examined the proportion of patients lost to follow-up among the 4810 treatment-naïve patients with complete baseline data and a least one follow-up visit ( Table 2 ). The median duration of follow-up was 0.97 year (interquartile range: 0.41-1.93 years). Loss to follow-up was defined as the proportion of patients who were seen in the first year of therapy and who should have been, but were not, seen in the subsequent year. A total of 727 such patients (15%) were identified. The percentage lost to follow-up across clinics ranged from 3.7 to 44%. Further analysis of the patterns of early loss to treatment and their determinants is in progress. 18 In particular, it is important to clarify in what proportion of patients loss to follow-up in a given treatment centre is equivalent to stopping antiretroviral treatment, and progression to death.
What has ART-LINC found?
The descriptive analyses presented above show that only 39% of the participating clinics were publicly funded, indicating that the private health sector, profit-oriented or not, plays an important role in the delivery of HAART in lower income countries. The important contribution of NGO's raises the issue of the long-term sustainability of treatment programmes. Among the 12 centres charging patients for care, the median cost per year of treatment represented a substantial proportion of the per capita income in low-income countries. 17 The 'inverse equity hypothesis', 19 which stipulates that health inequities will get worse as effective new public health interventions initially reach those of higher socioeconomic status and only later the poor, may, therefore, be borne out in the case of HAART in resource-poor settings. 20 The baseline data also indicate important differences between patients with and without follow-up information, and with and without baseline CD4 count, in terms of the type of clinic accessed (e.g. public or private) and the sociodemographic and clinical characteristics of patients. The combinations of antiretroviral drugs used generally correspond to the WHO recommendations, 16 indicating that these guidelines are useful, applicable, and, in principle, followed by public and private providers. In many centres laboratory follow-up, including CD4 count was not systematically performed. This is probably the result of technical and cost limitations rather than an attempt to simplify laboratory monitoring, an approach that requires proper evaluation. 21 Analyses comparing survival during the first year of HAART in ART-LINC with early mortality in high-income countries (data from the ART Cohort Collaboration 1, 22 ) have recently been presented. 23 The analysis is based on the 4810 ART-LINC patients with complete baseline data (Table 1) , and 165 deaths during 3744 person-years of follow-up. We used Weibull random effect survival models. The random effect, or shared frailty, is used to describe the unaccounted for heterogeneity between treatment programmes, which leads to the differential survival patterns. 24, 25 Models included both individual level (age, sex, baseline CD4 cell count, and type of initial regimen) and programme level characteristics (free access to treatment, use of generic drugs, routine monitoring of virologic response, tuberculosis clinic on site, and intensity of efforts to trace patients).
period of HAART initiation The results will be presented in detail elsewhere. Briefly, mortality rates fell dramatically within the first few months of potent antiretroviral treatment and approached those observed in Western Europe and North America after 4-6 months of HAART. Patients in low-income settings started potent antiretroviral treatment with considerably more advanced immunodeficiency than patients from industrialized countries in Western Europe and North America. Of note, the provision of treatment free of charge to patients was associated with lower mortality in low-income settings.
Strengths and weaknesses of the ART-LINC Collaboration
The ART-LINC Collaboration is, to our knowledge, the first to describe and compare ART programmes and their adult patients in a wide range of resource-constrained settings from three continents, after a recent report describing 598 patients treated with HAART in 11 sites in Asia. 26 Important strengths include the large number of clinics and cohorts participating, with a sizeable number of patients being included in the analysis. These treatment centres and their patients represent a broad diversity of types of programmes, patients, and delivery methods. ART-LINC also examines the intersection between programme and patient characteristics, and will be able in future analyses to more fully examine the impact of programme level characteristics on patient outcomes. Finally, it demonstrates the feasibility of assembling such an international collaborative database of treatment cohorts. The large number of patients and events is a strength however, follow-up is still limited. Also, ART-LINC is currently restricted to adult patients and results are not applicable to infants and children. The inclusion of infants and children is an important objective for future updates. Loss to follow-up might bias results if attrition is informative, i.e. associated with mortality. This has recently been demonstrated in a randomized trial in Abidjan, Cô te d'Ivoire. 27 We will examine this issue in detail and consider analyses of a combined endpoint of death or lost to follow-up. CD4 cell counts were available only in selected patients who may differ in important respects, for example in their adherence to therapy or access to care. ART-LINC data on causes of death, co-morbidities, and access to prophylaxis and treatment for opportunistic infections are also incomplete at present. ART-LINC is an ongoing initiative, which will continue to monitor outcomes in HIV-1-infected patients on HAART in lowincome settings, and update analyses at regular intervals. The improvement and harmonization of the collection of baseline and follow-up data is an important goal for the next update of the collaborative database.
Can I get hold of the data? Where can I find out more?
Collaborators sign an agreement to allow their data to be used in ART-LINC, however, the data remain the property of the participating centres and all analyses have to be approved by the Steering Group (see Appendix). Eligible treatment programmes can gain access to the data by joining ART-LINC. Readers who wish to find out more should visit the ART-LINC website at www.art-linc.org.
